|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACAD8 |
Gene summary for ACAD8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACAD8 | Gene ID | 27034 |
| Gene name | acyl-CoA dehydrogenase family member 8 | |
| Gene Alias | ACAD-8 | |
| Cytomap | 11q25 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q9UKU7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27034 | ACAD8 | HCC1_Meng | Human | Liver | HCC | 1.80e-52 | 8.26e-02 | 0.0246 |
| 27034 | ACAD8 | HCC2 | Human | Liver | HCC | 3.53e-02 | 1.37e+00 | 0.5341 |
| 27034 | ACAD8 | S014 | Human | Liver | HCC | 1.69e-09 | 3.91e-01 | 0.2254 |
| 27034 | ACAD8 | S015 | Human | Liver | HCC | 5.05e-15 | 5.20e-01 | 0.2375 |
| 27034 | ACAD8 | S016 | Human | Liver | HCC | 2.28e-11 | 4.38e-01 | 0.2243 |
| 27034 | ACAD8 | S028 | Human | Liver | HCC | 9.93e-04 | 2.16e-01 | 0.2503 |
| 27034 | ACAD8 | S029 | Human | Liver | HCC | 4.58e-02 | 2.63e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
| GO:001605421 | Liver | HCC | organic acid catabolic process | 152/7958 | 240/18723 | 5.11e-11 | 1.92e-09 | 152 |
| GO:00463952 | Liver | HCC | carboxylic acid catabolic process | 149/7958 | 236/18723 | 1.11e-10 | 3.87e-09 | 149 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:00090632 | Liver | HCC | cellular amino acid catabolic process | 70/7958 | 110/18723 | 6.12e-06 | 7.52e-05 | 70 |
| GO:00090812 | Liver | HCC | branched-chain amino acid metabolic process | 16/7958 | 19/18723 | 2.37e-04 | 1.79e-03 | 16 |
| GO:000908321 | Liver | HCC | branched-chain amino acid catabolic process | 13/7958 | 15/18723 | 5.67e-04 | 3.61e-03 | 13 |
| GO:00090835 | Prostate | Tumor | branched-chain amino acid catabolic process | 8/3246 | 15/18723 | 1.63e-03 | 9.79e-03 | 8 |
| GO:00090814 | Prostate | Tumor | branched-chain amino acid metabolic process | 8/3246 | 19/18723 | 1.00e-02 | 4.20e-02 | 8 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0028041 | Liver | HCC | Valine, leucine and isoleucine degradation | 41/4020 | 48/8465 | 4.84e-08 | 7.05e-07 | 3.92e-07 | 41 |
| hsa0028051 | Liver | HCC | Valine, leucine and isoleucine degradation | 41/4020 | 48/8465 | 4.84e-08 | 7.05e-07 | 3.92e-07 | 41 |
| hsa002807 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
| hsa0028012 | Prostate | Tumor | Valine, leucine and isoleucine degradation | 20/1791 | 48/8465 | 1.03e-03 | 4.59e-03 | 2.84e-03 | 20 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACAD8 | SNV | Missense_Mutation | c.926T>C | p.Leu309Pro | p.L309P | Q9UKU7 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| ACAD8 | SNV | Missense_Mutation | novel | c.1182C>G | p.His394Gln | p.H394Q | Q9UKU7 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| ACAD8 | SNV | Missense_Mutation | rs121908420 | c.988C>T | p.Arg330Trp | p.R330W | Q9UKU7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ACAD8 | SNV | Missense_Mutation | rs372521286 | c.986N>T | p.Ala329Val | p.A329V | Q9UKU7 | protein_coding | deleterious(0) | benign(0.193) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACAD8 | SNV | Missense_Mutation | rs142790411 | c.806C>T | p.Ala269Val | p.A269V | Q9UKU7 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ACAD8 | SNV | Missense_Mutation | rs374584216 | c.443N>T | p.Pro148Leu | p.P148L | Q9UKU7 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| ACAD8 | SNV | Missense_Mutation | c.85N>T | p.Arg29Trp | p.R29W | Q9UKU7 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACAD8 | SNV | Missense_Mutation | c.210N>T | p.Lys70Asn | p.K70N | Q9UKU7 | protein_coding | tolerated(0.18) | benign(0.085) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACAD8 | SNV | Missense_Mutation | novel | c.459N>T | p.Glu153Asp | p.E153D | Q9UKU7 | protein_coding | tolerated(0.26) | benign(0.007) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ACAD8 | SNV | Missense_Mutation | novel | c.469N>G | p.Ser157Ala | p.S157A | Q9UKU7 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |